Cara Therapeutics (CARA) Stock Forecast, Price Target & Predictions
CARA Stock Forecast
Cara Therapeutics stock forecast is as follows: an average price target of $14.50 (represents a 4718.88% upside from CARA’s last price of $0.30) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CARA Price Target
CARA Analyst Ratings
Buy
Cara Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 13, 2024 | Sumant Kulkarni | Canaccord Genuity | $1.00 | $0.68 | 47.17% | 232.34% |
Jun 12, 2024 | Annabel Samimy | Stifel Nicolaus | $1.00 | $0.68 | 47.17% | 232.34% |
May 10, 2022 | Oren Livnat | H.C. Wainwright | $30.00 | $9.23 | 225.03% | 9870.09% |
Mar 03, 2022 | Joseph Stringer | Needham | $26.00 | $11.08 | 134.66% | 8540.74% |
10
Cara Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $1.00 |
Last Closing Price | $0.30 | $0.30 | $0.30 |
Upside/Downside | -100.00% | -100.00% | 232.34% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 13, 2024 | Needham | Buy | Buy | Hold |
Jun 13, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
Jun 13, 2024 | Needham | Buy | Hold | Downgrade |
Jun 13, 2024 | Canaccord Genuity | Underperform | Negative | Downgrade |
May 14, 2024 | Needham | Buy | Buy | Hold |
May 14, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
Mar 28, 2024 | Needham | Buy | Buy | Hold |
Mar 28, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
Mar 05, 2024 | Needham | Buy | Buy | Hold |
Dec 19, 2023 | Piper Sandler | Buy | Buy | Hold |
10
Cara Therapeutics Financial Forecast
Cara Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $3.00M | $4.87M | $6.93M | $6.17M | $3.26M | $10.81M | $23.00M | $4.79M | $821.00K | $20.27M | - | $1.94M | $112.09M | $9.27M | $5.63M | $8.09M | $4.51M | $5.79M | $5.21M | $4.38M | $911.00K | $7.00K |
Avg Forecast | $600.00K | $800.00K | $1.00M | $1.20M | $1.69M | $2.02M | $1.18M | $1.68M | $9.42M | $9.95M | $6.50M | $4.89M | $14.50M | $8.84M | $21.11M | $2.64M | $1.46M | $15.59M | $2.59M | $3.02M | $5.97M | $4.73M | $5.01M | $4.71M | $5.39M | $4.84M | $3.06M | $3.29M | $832.27K | $7.54K |
High Forecast | $893.37K | $1.19M | $1.49M | $1.79M | $2.51M | $3.00M | $1.75M | $1.68M | $15.78M | $14.82M | $9.67M | $7.28M | $21.59M | $8.84M | $21.11M | $2.64M | $1.46M | $15.59M | $2.59M | $3.02M | $5.97M | $4.73M | $5.01M | $4.71M | $5.39M | $4.84M | $3.06M | $3.29M | $998.72K | $9.04K |
Low Forecast | $377.81K | $503.75K | $629.69K | $755.63K | $862.07K | $1.27M | $740.52K | $1.68M | $4.39M | $6.27M | $4.09M | $3.08M | $9.13M | $8.84M | $21.11M | $2.64M | $1.46M | $15.59M | $2.59M | $3.02M | $5.97M | $4.73M | $5.01M | $4.71M | $5.39M | $4.84M | $3.06M | $3.29M | $665.82K | $6.03K |
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 19 |
Surprise % | - | - | - | - | - | - | - | - | 0.32% | 0.49% | 1.07% | 1.26% | 0.22% | 1.22% | 1.09% | 1.82% | 0.56% | 1.30% | - | 0.64% | 18.76% | 1.96% | 1.12% | 1.72% | 0.84% | 1.19% | 1.70% | 1.33% | 1.09% | 0.93% |
Forecast
Cara Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 19 |
EBITDA | - | - | - | - | - | - | - | - | $-32.61M | $-28.03M | $-31.48M | $-27.59M | $-31.31M | $-23.84M | $-4.41M | $-27.85M | $-33.32M | $-951.00K | $-30.68M | $-23.24M | $78.72M | $-16.59M | $-25.20M | $-29.00M | $-28.73M | $-33.12M | $-23.14M | $-22.00M | $-22.11M | $-10.11M |
Avg Forecast | $-475.03K | $-633.37K | $-791.72K | $-950.06K | $-1.34M | $-1.60M | $-931.06K | $-25.10M | $-7.46M | $-7.88M | $-5.14M | $-26.85M | $-11.48M | $-7.00M | $-16.71M | $-28.71M | $-1.15M | $-12.34M | $-2.05M | $-27.96M | $-4.73M | $-3.74M | $-3.97M | $-29.00M | $-4.26M | $-3.83M | $-2.42M | $-22.75M | $-20.02M | $-10.83M |
High Forecast | $-299.12K | $-398.83K | $-498.54K | $-598.24K | $-682.51K | $-1.01M | $-586.28K | $-20.08M | $-3.47M | $-4.96M | $-3.24M | $-21.48M | $-7.23M | $-7.00M | $-16.71M | $-22.97M | $-1.15M | $-12.34M | $-2.05M | $-22.37M | $-4.73M | $-3.74M | $-3.97M | $-23.20M | $-4.26M | $-3.83M | $-2.42M | $-18.20M | $-16.02M | $-8.66M |
Low Forecast | $-707.29K | $-943.06K | $-1.18M | $-1.41M | $-1.99M | $-2.38M | $-1.39M | $-30.12M | $-12.50M | $-11.73M | $-7.66M | $-32.21M | $-17.10M | $-7.00M | $-16.71M | $-34.45M | $-1.15M | $-12.34M | $-2.05M | $-33.56M | $-4.73M | $-3.74M | $-3.97M | $-34.80M | $-4.26M | $-3.83M | $-2.42M | $-27.30M | $-24.03M | $-12.99M |
Surprise % | - | - | - | - | - | - | - | - | 4.37% | 3.56% | 6.12% | 1.03% | 2.73% | 3.41% | 0.26% | 0.97% | 28.86% | 0.08% | 14.95% | 0.83% | -16.64% | 4.43% | 6.35% | 1.00% | 6.74% | 8.64% | 9.57% | 0.97% | 1.10% | 0.93% |
Forecast
Cara Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 19 |
Net Income | - | - | - | - | - | - | - | - | $-32.34M | $-28.03M | $-31.48M | $-25.68M | $-29.37M | $-22.52M | $-3.94M | $-27.59M | $-33.38M | $-1.01M | $-30.75M | $-23.30M | $78.91M | $-16.51M | $-25.07M | $-28.92M | $-28.61M | $-32.84M | $-22.96M | $-21.96M | $-22.20M | $-10.69M |
Avg Forecast | $-10.97M | $-12.61M | $-11.52M | $-10.97M | $-10.79M | $-13.16M | $-15.03M | $-25.16M | $-24.46M | $-28.52M | $-29.52M | $-26.91M | $160.47M | $-22.52M | $-14.31M | $-28.78M | $-27.99M | $-21.14M | $-30.01M | $-28.04M | $19.94M | $-32.68M | $-36.43M | $-28.92M | $-36.06M | $-31.68M | $-33.60M | $-22.72M | $-20.10M | $-11.46M |
High Forecast | $-5.69M | $-6.54M | $-5.97M | $-5.69M | $-5.99M | $-6.83M | $-7.79M | $-20.13M | $-23.60M | $-14.79M | $-15.31M | $-21.53M | $192.57M | $-22.52M | $-14.31M | $-23.02M | $-27.99M | $-21.14M | $-30.01M | $-22.43M | $19.94M | $-32.68M | $-36.43M | $-23.14M | $-36.06M | $-31.68M | $-33.60M | $-18.17M | $-16.08M | $-9.16M |
Low Forecast | $-17.94M | $-20.63M | $-18.84M | $-17.94M | $-14.98M | $-21.53M | $-24.58M | $-30.19M | $-25.75M | $-46.65M | $-48.29M | $-32.29M | $128.38M | $-22.52M | $-14.31M | $-34.53M | $-27.99M | $-21.14M | $-30.01M | $-33.65M | $19.94M | $-32.68M | $-36.43M | $-34.71M | $-36.06M | $-31.68M | $-33.60M | $-27.26M | $-24.12M | $-13.75M |
Surprise % | - | - | - | - | - | - | - | - | 1.32% | 0.98% | 1.07% | 0.95% | -0.18% | 1.00% | 0.28% | 0.96% | 1.19% | 0.05% | 1.02% | 0.83% | 3.96% | 0.51% | 0.69% | 1.00% | 0.79% | 1.04% | 0.68% | 0.97% | 1.10% | 0.93% |
Forecast
Cara Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 19 |
SG&A | - | - | - | - | - | - | - | - | $6.59M | $6.75M | $7.54M | $6.86M | $6.43M | $6.91M | $7.54M | $9.31M | $11.48M | $5.85M | $5.62M | $6.37M | $6.66M | $5.22M | $5.41M | $4.56M | $4.62M | $4.23M | $4.99M | $3.91M | $2.40M | $2.45M |
Avg Forecast | $524.62K | $699.49K | $874.36K | $1.05M | $1.48M | $1.76M | $1.03M | $1.47M | $8.24M | $8.70M | $5.68M | $4.28M | $13.54M | $7.73M | $18.45M | $2.31M | $1.28M | $13.63M | $2.27M | $2.64M | $5.22M | $4.13M | $4.38M | $4.56M | $4.71M | $4.24M | $2.67M | $2.88M | $727.71K | $6.59K |
High Forecast | $781.13K | $1.04M | $1.30M | $1.56M | $2.19M | $2.63M | $1.53M | $1.47M | $13.80M | $12.95M | $8.46M | $6.37M | $16.25M | $7.73M | $18.45M | $2.31M | $1.28M | $13.63M | $2.27M | $2.64M | $5.22M | $4.13M | $4.38M | $5.47M | $4.71M | $4.24M | $2.67M | $2.88M | $873.25K | $7.91K |
Low Forecast | $330.35K | $440.46K | $550.58K | $660.69K | $753.76K | $1.11M | $647.48K | $1.47M | $3.84M | $5.48M | $3.58M | $2.69M | $10.83M | $7.73M | $18.45M | $2.31M | $1.28M | $13.63M | $2.27M | $2.64M | $5.22M | $4.13M | $4.38M | $3.65M | $4.71M | $4.24M | $2.67M | $2.88M | $582.16K | $5.27K |
Surprise % | - | - | - | - | - | - | - | - | 0.80% | 0.78% | 1.33% | 1.60% | 0.47% | 0.89% | 0.41% | 4.04% | 9.00% | 0.43% | 2.48% | 2.41% | 1.27% | 1.26% | 1.23% | 1.00% | 0.98% | 1.00% | 1.87% | 1.36% | 3.30% | 371.32% |
Forecast
Cara Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 19 |
EPS | - | - | - | - | - | - | - | - | $-0.59 | $-0.00 | $-0.00 | $-0.48 | $-0.55 | $-0.42 | $-0.07 | $-0.52 | $-0.63 | $-0.02 | $-0.61 | $-0.47 | $1.68 | $-0.35 | $-0.54 | $-0.62 | $-0.61 | $-0.74 | $-0.58 | $-0.56 | $-0.81 | $-0.39 |
Avg Forecast | $-0.20 | $-0.23 | $-0.21 | $-0.20 | $-0.20 | $-0.24 | $-0.27 | $-0.40 | $-0.45 | $-0.52 | $-0.54 | $-0.51 | $-0.34 | $-0.41 | $-0.26 | $-0.55 | $-0.51 | $-0.39 | $-0.55 | $-0.57 | $0.36 | $-0.60 | $-0.67 | $-0.60 | $-0.66 | $-0.58 | $-0.61 | $-0.58 | $-0.67 | $-0.45 |
High Forecast | $-0.10 | $-0.12 | $-0.11 | $-0.10 | $-0.11 | $-0.12 | $-0.14 | $-0.21 | $-0.43 | $-0.27 | $-0.28 | $-0.27 | $-0.18 | $-0.41 | $-0.26 | $-0.55 | $-0.51 | $-0.39 | $-0.55 | $-0.57 | $0.36 | $-0.60 | $-0.67 | $-0.60 | $-0.66 | $-0.58 | $-0.61 | $-0.58 | $-0.54 | $-0.36 |
Low Forecast | $-0.33 | $-0.38 | $-0.34 | $-0.33 | $-0.27 | $-0.39 | $-0.45 | $-0.65 | $-0.47 | $-0.85 | $-0.88 | $-0.84 | $-0.56 | $-0.41 | $-0.26 | $-0.55 | $-0.51 | $-0.39 | $-0.55 | $-0.57 | $0.36 | $-0.60 | $-0.67 | $-0.60 | $-0.66 | $-0.58 | $-0.61 | $-0.58 | $-0.80 | $-0.54 |
Surprise % | - | - | - | - | - | - | - | - | 1.32% | 0.00% | 0.00% | 0.94% | 1.60% | 1.02% | 0.28% | 0.94% | 1.23% | 0.05% | 1.11% | 0.82% | 4.62% | 0.59% | 0.81% | 1.03% | 0.93% | 1.28% | 0.94% | 0.97% | 1.21% | 0.87% |
Forecast